Eton Pharmaceuticals, Inc. (ETON) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Earnings Reports
-
Eton Pharmaceuticals (ETON) Q1 2026: Guidance Raised 9% as Hemangiol Launch Bolsters Rare Disease Runway
May 15, 2026
-
Eton Pharmaceuticals (ETON) Q4 2025: EBITDA Margin Jumps to 29% as Rare Disease Portfolio Expands
March 20, 2026
-
Eton Pharmaceuticals (ETON) Q3 2025: Margin Set to Jump 25 Points as Product Mix Shifts
November 07, 2025
-
ETON (ETON) Q2 2025: Increlex Patient Base Surges 49%, Accelerating Revenue Run Rate Timeline
August 08, 2025
-
ETON Q1 2025: Product Sales Jump 76% as Rare Disease Pipeline Accelerates
July 06, 2025